BDMD

3 - Baird Medical Investment Holdings Ltd (0001982444) (Issuer)

3 - Baird Medical Investment Holdings Ltd (0001982444) (Issuer)

3 - Baird Medical Investment Holdings Ltd (0001982444) (Issuer)

3 - Baird Medical Investment Holdings Ltd (0001982444) (Issuer)

3 - Baird Medical Investment Holdings Ltd (0001982444) (Issuer)

3 - Baird Medical Investment Holdings Ltd (0001982444) (Issuer)

3 - Baird Medical Investment Holdings Ltd (0001982444) (Issuer)

3 - Baird Medical Investment Holdings Ltd (0001982444) (Issuer)

NEW YORK, March 16, 2026 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ:BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced the successful execution of two clinical training workshops in Indonesia. This initiative supports the Company's strategic expansion in Southeast Asia by providing regional healthcare providers with the practical knowledge and advanced tools needed to enhance patient care. Hosted at EKA Medika Hospital and RSCM Rumah Sakit Nasional Dr. Cipto Mangunkusumo Hospita

NEW YORK, March 12, 2026 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ:BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced the regulatory clearance of its systems in Argentina. This milestone drives the Company's international growth, supporting a broader mission to expand patient access to highly effective, minimally invasive therapies worldwide. The Argentine approval strengthens Baird Medical's growing portfolio of international certifications, which includes the United States FD

S-8 - Baird Medical Investment Holdings Ltd (0001982444) (Filer)

NEW YORK, March 9, 2026 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ:BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced its successful strategic showcase at the 2026 North American Society for Interventional Thyroidology (NASIT) in Portland, Oregon. This engagement advances the Company's goal to expand patient access to advanced, minimally invasive treatment options. Baird Medical's proprietary MWA platforms garnered significant interest during the event's thermal ablation worksho

NEW YORK, March 4, 2026 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ:BDMD) ("Baird Medical"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced the successful completion of development for its cross-platform surgical software, officially commencing the registration process in the United States, the European Union, and China. Leveraging a proprietary artificial intelligence model, the system automates core clinical workflows, including anatomical mapping, dynamic treatment planning, and procedural simulations. By integrat

NEW YORK, March 2, 2026 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ:BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced its participation at the 2026 North American Society of Interventional Endocrinologists (NASOIE) Annual Meeting in Miami, Florida. Building on successful engagements at previous NASOIE gatherings, this initiative reinforces the Company's enduring commitment to physician education and advances its strategy to expand patient access to minimally invasive therapies.

NEW YORK, Feb. 25, 2026 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ:BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced new clinical progress across the United States. This momentum directly supports the Company's strategy to accelerate global growth and expand patient access to advanced, minimally invasive therapies. Reinforcing the Company's market leadership in the western United States, Samer Nakhle, M.D., FACE, ECNU, Medical Director of Palm Medical Group in Las Vegas, Nevada

NEW YORK, Feb. 19, 2026 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ:BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced its participation for three major clinical conferences this quarter. These events are pivotal to the company's expansion, providing U.S. clinicians direct access to its innovative needle-based therapies for thyroid conditions. Baird Medical will join top interventionalists and surgeons to demonstrate how its proprietary technology treats benign nodules without th

NEW YORK, Feb. 11, 2026 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ:BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced the strategic commercial deployment of its technology at Bakersfield Memorial Hospital in California. This launch represents the first ablation case for Benign Thyroid Tumor (or "of its kind") in the vital central California hub of the San Joaquin Valley. This development reinforces Baird Medical's commitment to accelerating patient access to advanced care and solidifies the Company's expanding footprint in key U.S. regional markets.

6-K - Baird Medical Investment Holdings Ltd (0001982444) (Filer)

NEW YORK, Feb. 9, 2026 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ:BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced the execution of premier clinical education programs in the United States and Japan. These strategic engagements reinforce Baird Medical's market leadership and accelerate its global expansion by establishing standardized clinical excellence for interventional thyroidology. In New York, the Company successfully facilitated an advanced training initiative at the

NEW YORK, Jan. 28, 2026  /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ:BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced the successful conclusion of its Gynecological Microwave Ablation Masterclass in Shanghai. Led by Dr. Xiaoming Gong of Weheal, the program offered a rigorous curriculum designed to advance procedural expertise in the treatment of benign gynecological conditions using the Company's proprietary technology. The event featured a combination of expert-led didactic

NEW YORK, Jan. 26, 2026 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ:BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced a strategic partnership with Stonewood Key Capital, a wholly-owned comprehensive investment management enterprise from New Zealand. This collaboration positions the Hainan Free Trade Port as a pivotal hub for the Company's cross-border operations and supply chain, enabling more efficient capital allocation to accelerate the commercialization of its advanced medical solutions globally.

NEW YORK, Jan. 20, 2026 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ:BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced its successful participation in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. During the conference week, the Company's leadership team, including U.S. CEO Mark Saxton, held a series of meetings with institutional investors and healthcare industry veterans. These discussions focused on Baird Medical's 2026 strategic priorities, specificall

424B3 - Baird Medical Investment Holdings Ltd (0001982444) (Filer)

EFFECT - Baird Medical Investment Holdings Ltd (0001982444) (Filer)

NEW YORK, Jan. 7, 2026 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ:BDMD) ("Baird Medical" or the "Company"), a market leader in Microwave Ablation (MWA) technology, today announced it has reached key regulatory milestones with official product registrations from both the Medical Device Board (MDB) of Pakistan and the Ministry of Health of Vietnam. In Pakistan, the Company successfully executed its official product launch at the Armed Forces Institute of Radiology & Imaging (AFIRI). The launch was conducted under the professional guidance of Dr. Raza Raheem,